|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
These excerpts taken from the OSUR 10-K filed Mar 10, 2009. Performance Graph The performance graph set forth below shall not be deemed soliciting material or filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to liability under that Section. This graph will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether such filing occurs before or after the date hereof, regardless of any general incorporation language in such filing. The following graph compares the cumulative total returns to investors in the Companys Common Stock, the NASDAQ Composite Index and the NASDAQ Biotechnology Index for the period from December 31, 2003 through December 31, 2008. The graph assumes that $100 was invested on December 31, 2003 in the Companys Common Stock and in each of the above-mentioned indices, and that all dividends, if any, were reinvested. The NASDAQ Composite Index was chosen because it is a broad index of companies whose equity securities are traded on the NASDAQ Stock Market. The NASDAQ Biotechnology Index was chosen because it includes a number of our competitors. Stockholders are cautioned that the graph shows the returns to investors only as of the dates noted and may not be representative of the returns for any other past or future period.
40
Table of Contents
The following table sets forth selected financial data of the Company. This information should be read in conjunction with the Financial Statements and notes thereto included in Item 15 and the information set forth in Item 7, Managements Discussion and Analysis of Financial Condition and Results of Operations. Performance Graph FACE="Times New Roman" SIZE="2">The performance graph set forth below shall not be deemed soliciting material or filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange The following graph compares the FACE="Times New Roman" SIZE="2">The NASDAQ Composite Index was chosen because it is a broad index of companies whose equity securities are traded on the NASDAQ Stock Market. The NASDAQ Biotechnology Index was chosen because it includes a number of
40 Table of Contents
SIZE="2">The following table sets forth selected financial data of the Company. This information should be read in conjunction with the Financial Statements and notes thereto included in Item 15 and the information set forth in Item 7, These excerpts taken from the OSUR 10-K filed Mar 12, 2008. Performance Graph The following graph compares the cumulative total returns to investors in the Companys Common Stock, the NASDAQ Composite Index and the NASDAQ Biotechnology Index for the period from December 31, 2002 through December 31, 2007. The graph assumes that $100 was invested on December 31, 2002 in the Companys Common Stock and in each of the above-mentioned indices, and that all dividends were reinvested. The NASDAQ Composite Index was chosen because it is a broad index of companies whose equity securities are traded on the NASDAQ Stock Market. The NASDAQ Biotechnology Index was chosen because it includes a number of our competitors. Stockholders are cautioned that the graph shows the returns to investors only as of the dates noted and may not be representative of the returns for any other past or future period.
The performance graph set forth above shall not be deemed soliciting material or filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to liability under that Section. This graph will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether such filing occurs before or after the date hereof, regardless of any general incorporation language in such filing.
38
Table of ContentsPerformance Graph FACE="Times New Roman" SIZE="2">The following graph compares the cumulative total returns to investors in the Companys Common Stock, the NASDAQ Composite Index and the NASDAQ Biotechnology Index for the period from December 31, 2002 Biotechnology Index was chosen because it includes a number of our competitors. Stockholders are cautioned that the graph shows the returns to investors only as of the dates noted and may not be representative of the returns for any other past or future period.
The performance graph set forth above shall not be deemed soliciting material or 38 Table of ContentsThis excerpt taken from the OSUR 10-K filed Mar 16, 2007. Performance Graph
The following graph compares the cumulative total returns to investors in the Companys Common Stock, the NASDAQ Composite Index and the NASDAQ Biotechnology Index for the period from December 31, 2001 through December 31, 2006. The graph assumes that $100 was invested on December 31, 2001 in the Companys Common Stock and in each of the above-mentioned indices, and that all dividends were reinvested.
The NASDAQ Composite Index was chosen because it is a broad index of companies whose equity securities are traded on the NASDAQ Stock Market. The NASDAQ Biotechnology Index was chosen because it includes a number of our competitors. Stockholders are cautioned that the graph shows the returns to investors only as of the dates noted and may not be representative of the returns for any other past or future period.
The performance graph set forth above shall not be deemed soliciting material or filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to liability under that Section. This graph will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether such filing occurs before or after the date hereof, regardless of any general incorporation language in such filing.
36
Table of Contents | EXCERPTS ON THIS PAGE:
RELATED TOPICS for OSUR: |
| |||||||